SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Aziz Mottiwala of Tarsus Pharmaceuticals discusses Xdemvy for the treatment of Demodex blepharitis.
Mottiwala overviews the educational efforts and distribution approach for Xdemvy (lotilaner ophthalmic solution 0.25%).
“You can think about our educational efforts in terms of increasing diagnosis and then sending the value of treatment for those patients,” he said.
Xdemvy is the first product approved for the treatment of Demodex blepharitis.